STAT3 and neoplasm: A statistical analysis of all 42 tumour samples, including EATL I, EATL II and PTCL-NOS, revealed the activation of STAT3 in 82.35% of all tumour cells examined, as determined by the ratio between cytoplasmic and nuclear localisation.